Should more MDS patients be treated with immune-suppression?

Despite the fact that the emergence of neoplastic hematopoietic clones are the central pathophysiological events in MDS [1], many other mechanisms are required to ensure the survival, proliferation and predominance of these clones over normal hematopoiesis. The need for these accessory mechanisms is attested by the recent findings that clonal hematopoesis per se is not sufficient to generate MDS [2]. MDS clones are aided in their survival by changes in bone marrow stroma [3] and immune dysregulation, both of which are likely to be generated by the MDS clone itself [4].

Source: Leukemia Research - June 19, 2018 Category: Hematology Authors: Antonio Almeida Source Type: research